Latest Articles about AMGN

Stock Market News for May 22, 2013 - Market News

Zacks Equity Research — Wed, 22 May 2013 18:32:13 Z

Benchmarks eked out gains after a Federal Reserve official clarified doubt on monetary stimulus on Tuesday. The lack of catalysts resulted in the absence of any major movement in the

Market Close Report: NASDAQ Composite index closes at 3,496.43 down -2.54 points

NASDAQ.com News — Tue, 21 May 2013 00:45:13 Z

Monday's session closes with the NASDAQ Composite Index at 3,496.43. The total shares traded for the NASDAQ was over 1.69 billion. Advancers stocks led declining by 1.19 to 1 ratio. There were

Sanofi/REGN Commence Enrollment - Analyst Blog

Zacks Equity Research — Thu, 16 May 2013 01:28:51 Z

Sanofi ( SNY ) and partner Regeneron Pharmaceuticals, Inc. ( REGN ) recently announced that they started enrolling patients for two phase III trials (SARIL-RA COMPARE and SARIL-RA

Amgen to Set Up JV in China - Analyst Blog

Zacks Equity Research — Wed, 15 May 2013 01:05:29 Z

Amgen ( AMGN ) recently announced its intention to set up a joint venture (JV) in China with Zhejiang Beta Pharma Co., Ltd. The JV will focus on the commercialization of Amgen's

Stock Market News for May 14, 2013 - Market News

Zacks Equity Research — Tue, 14 May 2013 18:36:01 Z

Major indices finished mixed following better-than-expected retail sales data and discouraging economic reports from China. Investors are also concerned that, in light of encouraging economic

Stock Market News for May 13, 2013 - Market News

Zacks Equity Research — Mon, 13 May 2013 18:18:31 Z

Benchmarks finished in the green riding on positive investor sentiment. A few better-than-expected corporate results added to the prevailing optimism. Meanwhile, the Federal Reserve discussed

Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 14, 2013

NASDAQ.com News — Mon, 13 May 2013 15:39:06 Z

Amgen Inc. ( AMGN ) will begin trading ex-dividend on May 14, 2013. A cash dividend payment of $0.47 per share is scheduled to be paid on June 07, 2013. Shareholders who purchased AMGN stock

Q1 Revenue In-Line. Amgen Deal Is Encouraging - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 17:24:44 Z

By Brian Marckx, CFA Q1 2013 RESULTS: Revenue In-Line, EPS Miss on Higher SG&A. Amgen Deal is Encouraging… Transgenomic (OTC: TBIO ) reported financial results for Q1

S&P Highlights Biotech ETFs

ETF Professor — Fri, 10 May 2013 15:39:21 Z

Bolstered by an accommodating Food & Drug Administration and promising recent clinical results for drugs aimed at treating conditions such as hepatitis C and multiple sclerosis,

Amgen, Inc. (AMGN): Today's Most Compelling Stock Buy

David Moenning — Thu, 09 May 2013 20:55:48 Z

SoTM Bull's Eye Report - Today's Most Compelling Buy Thursday, May 9, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the

X Factor: 5 Stocks Reaching Their Ex-Dividend Date on May 14

Christopher Witrak — Tue, 07 May 2013 17:07:00 Z

Many stocks will reach their ex-dividend date next Tuesday, which is significant for investors as the seller of the stock on that date, not the buyer, receives the most recent dividend. A

Techne Corporation (TECH) Ex-Dividend Date Scheduled for May 08, 2013

NASDAQ.com News — Tue, 07 May 2013 17:00:03 Z

Techne Corporation ( TECH ) will begin trading ex-dividend on May 08, 2013. A cash dividend payment of $0.3 per share is scheduled to be paid on May 24, 2013. Shareholders who purchased TECH

Top Fund Buys Focus On Defensive Stocks, Housing

Investor's Business Daily — Fri, 03 May 2013 01:45:00 Z

April notched another month of gains for the stock market. That's four straight months so far this year. But this market rally is getting long in the tooth and top fund managers have been

Earnings Beat at Hospira - Analyst Blog

Mark Vickery — Wed, 01 May 2013 21:10:01 Z

Hospira Inc. 's ( HSP ) first quarter 2013 adjusted earnings of 52 cents per share beat the Zacks Consensus Estimate of 44 cents. Higher-than-expected revenues led to the earnings beat.

Is the Biotech Sector Still a Market Leader? - Real Time Insight

Eric Dutram — Thu, 25 Apr 2013 19:18:48 Z

The biotechnology sector has been a strong performer for much of 2013. The space has seen huge gains over and above that of the broad market, with biotech benchmarks outpacing the S&P